A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)

The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Psoriasis
What the trial is testing?
Mirikizumab
Could I receive a Placebo?
No
Enrollment Goal
1936
Trial Dates
Sep 3, 2018 - Feb 7, 2022
How long will I be in the trial?
The study will last about 220 weeks and may include up to 23 visits.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have completed the last visit of an eligible study period of originating study

  • Participants must be willing to follow the birth control measures during and after study treatment if woman of childbearing potential

Participants Must Not:

  • Participants must not have an unstable or uncontrolled illness, including but not limited to a cerebro-cardiovascular, respiratory, liver, kidney, gastrointestinal, endocrine, blood, or neurologic disease or abnormal lab results, that the study investigator thinks makes it unsafe or inappropriate for the participant to participate in this study

  • Participants must not have stopped taking mirikizumab during a previous study if the study investigator does not think the participant should resume taking mirikizumab

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.